2020
Radiation Therapy for Patients with Advanced Renal Cell Carcinoma
Miccio JA, Oladeru OT, Jun S, Johung KL. Radiation Therapy for Patients with Advanced Renal Cell Carcinoma. Urologic Clinics Of North America 2020, 47: 399-411. PMID: 32600541, DOI: 10.1016/j.ucl.2020.04.011.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaRadiation therapyMetastatic renal cell carcinomaExcellent local controlUse of radiotherapyBody radiation therapySelect patientsSurgical candidatesMetastatic sitesSurvival outcomesPrimary tumorImmune responseStereotactic radiosurgeryLocal controlPatientsMinimal toxicityCarcinomaTherapyFuture studiesPalliationRadiotherapyRadiosurgeryAssociation of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy
2019
When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.
Miccio J, Johung K. When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy. Oncology 2019, 33: 167-73, 177. PMID: 31095714.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyRenal cell carcinomaBody radiation therapyCell carcinomaRadiation therapyExcellent local control ratesMulti-fraction regimensExcellent local controlLocal control rateTreatment-related toxicityManagement of patientsSmall cohort sizeAdjuvant settingOligometastatic sitesNonsurgical patientsFraction radiationMetastatic sitesOnly palliationControl ratePrimary tumorTreatment approachesLocal controlCarcinomaTherapyPatients